Rosas-Peralta M, Medina-Concebida LE, Borrayo-Sánchez G, Madrid-Miller A, Ramírez-Arias E, Pérez-Rodríguez G

Idioma: Español
Referencias bibliográficas: 36
Paginas: 52-66
Archivo PDF: 409.82 Kb.

RESUMEN

La pandemia de la obesidad en el niño y adolescente, el riesgo de desarrollar hipertrofia ventricular y la evidencia del desarrollo temprano de la aterosclerosis hacen necesaria una detección temprana y una intervención oportuna en la hipertensión de la niñez para reducir riesgos de salud a largo plazo; sin embargo, los datos epidemiológicos de apoyo a las cifras de referencia son escasos. La hipertensión secundaria es más común en niños preadolescentes y una buena proporción está en relación a enfermedad renal. La hipertensión arterial sistémica esencial es más común en adolescentes y tiene múltiples factores de riesgo asociados, incluyendo obesidad y antecedentes familiares. La evaluación clínica integral implica una historia cuidadosa y un examen físico completo, pruebas de laboratorio y estudios especiales. Los tratamientos no farmacológicos incluyen la reducción del peso, ejercicio y modificaciones dietéticas. Las recomendaciones para el tratamiento farmacológico se basan sobre todo en la hipertensión sintomática, la evidencia de daño a órganos blanco y la hipertensión arterial que no se reduce con las modificaciones de la forma de vida, o bien, la hipertensión arterial asociada con diabetes mellitus, en la que la búsqueda de microalbuminuria está justificada.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Lomelí C, Rosas M, Mendoza-González C, Mendez A, Lorenzo JA, Buendía A, et al. Hipertensión arterial sistémica en el niño y adolescente. Arch Cardiol Mex. 2008;78 Supl 2: S2:82-93.

2. Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, et al. Management of high blood pressure in children and adolescents: recommendations of the European society of hypertension. J Hypertens. 2009;27:1719-42.

3. National High Blood Pressure Education Program Working Group on High Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatr. 2004;114:555-76.

4. Hofman A, Hazelbroek A, Valkenburd HA. A randomized trial of sodium intake and blood pressure in newborn infants. JAMA. 1983;250(3):370-3.

5. Spagnolo A, Giussani M, Ambruzzi AM, Bianchetti M, Maringhini S, Matteucci MC, et al. Focus on prevention, diagnosis and treatment of hypertension in children and adolescents Italian Journal of Pediatrics 2013, 39:20: 1-14.

6. Muñoz R, Romero B, Medeiros M, Velásquez L. Manejo y tratamiento de la hipertensión arterial en niños. Bol Med Hosp Infant Mex. 1997;54:335-43.

7. Matsuoka S, Awazu M. Masked hypertension in children and young adults. Pediatr Nephrol. 2004;19(6):651-4.

8. US Department of Health and Human Services. Centers for Disease Control and Prevention. National Center for Health Statistics. National Health and Nutrition Examination Survey. CDC Grown Charts: United States (acceded 2001 June, 4).

9. Freedman DS, Dietz WH, Srinivasan SR, Berenson GS. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics. 1999;103:1175-82.

10. Olaiz-Fernández G, Rivera-Dommarco J, Shamah- Levy T, Rojas R, Villalpando-Hernández S, Hernández- Avila M et al. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca, México: Instituto Nacional de Salud Pública; 2006.

11. Sorof JM, Poffenbarger T, Franco K, Bernard L, Portman RJ. Isolated systolic hipertension, obesity, and hyperkinetic hemodynamics states in children. J Pediatr. 2002;140(6):660-6.

12. World Health Organization (WHO). Programme of Nutrition, Family and Reproductive Health. Obesity. Preventing and managing the global epidemic. Report of a WHO consultation ond obesity. Geneva, 3-5 June, 1997. Geneva: WHO; 1998.

13. Sorof J, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. Hypertension. 2002;40:441-7.

14. Goodman E, Daniels SR, Morrison JA, Huang B, Dolan LM. Contrasting prevalence of and demographic disparities in the World Health Organization and National Cholesterol Education Program Adult Treatment Panel III definitions of metabolic syndrome among adolescents. J Pediatr. 2004;145(4):445-51.

15. Marcus CL, Greene MG, Carroll JL. Blood pressure in children with obstructive sleep apnea. Am J Respir Crit Care Med. 1998;157:1098-103.

16. Mindell JA, Owens JA. A clinical Guide to Pediatric Sleep: Diagnosis and Management of Sleep Problems. Philadelphia, PA: Lippincott Williams & Wilkins; 2003.

17. Guillery EN, Robillard JE. The Renin-Angiotensin System and blood pressure regulation during infancy and childhood. Pediatr Clin North Am. 1993;40:61-79.

18. Flynn JT. Evaluation and management of hypertension in childhood. Prog Pediatr Cardiol. 2001;12:177-88.

19. Bartsh SM, Aronson AJ. Childhood hypertension. An update on etiology, diagnosis, and treatment. Pediatr Clin North Am. 1999;46:235-52.

20. Flynn JT. Hypertension in adolescents. Adolesc Med Clin. 2005;16:111-29.

21. Santos RA, Campagnole-Santos MJ, Andrade SP. Angiotensin -(1-7): a update. Regul Pept. 2000;91:45-62.

22. Carey RM, Siragy HM. Newly recognized components of the Renin-Angiotensin System: potential roles in cardiovascular and renal regulation. Endocrine Rev. 2003;24:261-71.

23. Ferrario CM, Chappell MC, Dean RH, Iyer SN. Novel angiotensin peptides regulate blood pressure, endothelial function, and natriuresis. J Am Soc Nephrol. 1998;9:1716-22.

24. Campbell DJ. The Renin Angiotensin and Kallikrein Kinin Systems. Int J Biochem Cell Biol. 2003;35:784-91.

25. Simoes e Silva AC, Bello APC, Baracho NCV, Khosla MC, Santos RAS. Diuresis and natriuresis produced Rev Med Inst Mex Seguro Soc. 2016;54 Supl 1:S52-66 by long-term administration of a selective Angiotensin -(1-7) antagonist in normotensive and hypertensive rats. Regul Pept. 1998;74:177-84.

26. Santos RA, Haibara AS, Campagnole-Santos MJ, Simoes e Silva AC, Paula RD, Pinheiro SV et al. Characterization of a new selective antagonist for Angiotensin-( 1-7), D-Pro-Angiotensin-(1-7). Hypertension. 2003;41(3 Pt 2):737-43.

27. Simoes e Silva AC, Diniz JS, Regueira FA, Santos RAS. The renin angiotensin system in childhood hypertension: selective increase of angiotensin-(1-7) in essential hypertension. J Pediatr. 2004;145:93-8.

28. Hiner LB, Falkner B. Renovascular hypertension in children. Pediatr Clin North Am. 1993;40:123-40.

29. Dillon MJ, Ryness JM. Plasma renin activity and aldosterone concentration in children. Br Med J. 1975;4(5992):316-9.

30. Watson AR, Balfe JW, Hardy BE. Renovascular hypertension in childhood: a changing perspective in management. J Pediatr. 1985;106:366-372.

31. Dillon MJ. The diagnosis of renovascular disease. Pediatr Nephol 1997;11:366-72.

32. Daniels SR, Kimball TR, Morrison JA, Khoury P, Witt S, Meyer RA. Effect of lean body mass, blood pressure, and sexual maturation on left ventricular mass in children and adolescents. Statistical, biological, and clinical significance. Circulation. 1995;92:3249-54.

33. Still JL, Cottom D. Severe hypertension in childhood. Arch Dis Child. 1967;42:34-9.

34. Gill DG, Mendes de Costa B, Cameron JS, Joseph MC, Ogg CS, Chantler C. Analysis of 100 children with severe and persistent hypertension. Arch Dis Child. 1976;51(12):951-6.

35. Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid Intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation. 2001;104:2815-9.

36. Sorof JM, Cargo P, Graepel J, Humphrey D, King E, Rolf C, et al. Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr Nephrol. 2002;17:345-50.